Breast Cancer Research and Treatment

, Volume 130, Issue 1, pp 281–289 | Cite as

Pathological characteristics of BRCA-associated breast cancers in Hispanics

  • Veronica I. Lagos-Jaramillo
  • Michael F. Press
  • Charité N. Ricker
  • Louis Dubeau
  • Phuong L. Mai
  • Jeffrey N. Weitzel


The immunophenotype of BRCA-associated breast cancer has been studied in predominantly non-Hispanic whites (NHW). We evaluated the pathological characteristics of BRCA-associated invasive breast cancer in Hispanics. A case–control study was conducted on breast cancers from Hispanic and NHW women who enrolled in an IRB-approved registry and underwent BRCA gene analysis. BRCA negative controls (41 Hispanic, 39 NHW) were matched on age and ethnicity to BRCA positive cases (39 Hispanic, 35 NHW). A tissue array was constructed to characterize the expression of estrogen receptor (ER), progesterone receptor (PR), HER2, Ki-67 and p53 by immunohistochemistry. Mean age at diagnosis was 37.1 years (range 24–59) for Hispanics (80% with Mexican ancestry) and 40.1 years (range 21–63) for NHW (P = 0.03). Hispanic BRCA1 cases were more likely than BRCA negative controls to have tumors that were ER-negative (P < 0.001) and PR-negative (P = 0.001), had higher levels of Ki-67 (P = 0.001) and p53 expression, and lower levels of HER2 overexpression. When stratified by genes, there were no significant differences in expression of ER, Ki-67, HER2, and p53 by ethnicity among mutation carriers. However, a significantly higher proportion of BRCA-positive Hispanics had PR-negative tumors compared to BRCA-positive NHW (80 vs. 57%, OR = 2.9, 95% CI 1.0–8.1, P = 0.04). Hispanic BRCA-associated breast cancers were found to have the unique immunophenotype associated with BRCA mutations; however, there was a trend toward a difference in PR expression among Hispanic BRCA1 and BRCA2 cases. Additional research on the molecular mechanisms involved in the loss of PR in this population is warranted as it could have important implications for the treatment and prevention of breast cancer in Hispanics.


Hispanic Breast cancer BRCA Progesterone receptor Estrogen receptor 



We thank Sofia Loera and Peiguo Chu, MD, in the Pathology Core Laboratory at City of Hope National Medical Center for assistance with the construction of the multitumor tissue blocks, and Armen Gasparyan and Angela Santiago in the laboratory of Michael Press, MD, PhD, at the University of Southern California for assistance with immunohistochemistry. We also thank Hazel Mariveles, Lacolle Robinson and Sharon Sand for research support and Tracy Sulkin for assistance with the manuscript. These investigations were supported by grants from the Breast Cancer Research Foundation and Expedition Inspiration to MFP, by funds received under Grant Agreement No. 99-86874 and 00-92133 with the California Department of Health Services, Cancer Research Section, and support for PM from NIH Grant No. R25CA85771, and RC4CA153828 awarded to JNW.

Conflict of interest



  1. 1.
    ACS (2006) Cancer facts and figures for Hispanics/Latinos 2006–2008. American Cancer Society, AtlantaGoogle Scholar
  2. 2.
    Shavers VL, Harlan LC, Stevens JL (2003) Racial/ethnic variation in clinical presentation, treatment, and survival among breast cancer patients under age 35. Cancer 97(1):134–147PubMedCrossRefGoogle Scholar
  3. 3.
    Elledge RM, Clark GM, Chamness GC, Osborne CK (1994) Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst 86(9):705–712PubMedCrossRefGoogle Scholar
  4. 4.
    Frost F, Tollestrup K, Hunt WC, Gilliland F, Key CR, Urbina CE (1996) Breast cancer survival among New Mexico Hispanic, American Indian, and non-Hispanic white women (1973–1992). Cancer Epidemiol Biomark Prev 5(11):861–866Google Scholar
  5. 5.
    Boyle T, McPadden E (2004) Breast cancer presents at an earlier age in Mexican American women. Breast J 10(5):462–464PubMedCrossRefGoogle Scholar
  6. 6.
    Gapstur SM, Dupuis J, Gann P, Collila S, Winchester DP (1996) Hormone receptor status of breast tumors in black, Hispanic, and non-Hispanic white women. An analysis of 13, 239 cases. Cancer 77(8):1465–1471PubMedCrossRefGoogle Scholar
  7. 7.
    Li CI, Malone KE, Daling JR (2003) Differences in breast cancer stage, treatment, and survival by race and ethnicity. Arch Intern Med 163(1):49–56PubMedCrossRefGoogle Scholar
  8. 8.
    Chu KC, Anderson WF, Fritz A, Ries LA, Brawley OW (2001) Frequency distributions of breast cancer characteristics classified by estrogen receptor and progesterone receptor status for eight racial/ethnic groups. Cancer 92(1):37–45PubMedCrossRefGoogle Scholar
  9. 9.
    Pegoraro RJ, Karnan V, Nirmul D, Joubert SM (1986) Estrogen and progesterone receptors in breast cancer among women of different racial groups. Cancer Res 46(4 Pt 2):2117–2120PubMedGoogle Scholar
  10. 10.
    Lai H, Lai S, Ma F, Meng L, Trapido E (2003) Prevalence and spectrum of p53 mutations in white Hispanic and non-Hispanic women with breast cancer. Breast Cancer Res Treat 81(1):53–60PubMedCrossRefGoogle Scholar
  11. 11.
    Jacquemier J, Eisinger F, Birnbaum D, Sobol H (1995) Histoprognostic grade in BRCA1-associated breast cancer. Lancet 345(8963):1503PubMedCrossRefGoogle Scholar
  12. 12.
    Eisinger F, Jacquemier J, Charpin C, Stoppa-Lyonnet D, Bressac-de Paillerets B, Peyrat J-P, Longy M, Guinbretiere J-M, Sauvan R, Noguchi T, Birnbaum D, Sobol H (1998) Mutations at BRCA1: the medullary breast carcinoma revisited. Cancer Res 58:1588–1592PubMedGoogle Scholar
  13. 13.
    Foulkes WD, Stefansson IM, Chappuis PO, Begin LR, Goffin JR, Wong N, Trudel M, Akslen LA (2003) Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 95(19):1482–1485PubMedGoogle Scholar
  14. 14.
    Chang J, Hilsenbeck SG, Sng JH, Wong J, Ragu GC (2001) Pathological features and BRCA1 mutation screening in premenopausal breast cancer patients. Clin Cancer Res 7(6):1739–1742PubMedGoogle Scholar
  15. 15.
    Loman N, Johannsson O, Bendahl PO, Borg A, Ferno M, Olsson H (1998) Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer 83(2):310–319PubMedCrossRefGoogle Scholar
  16. 16.
    Foulkes WD, Metcalfe K, Sun P, Hanna WM, Lynch HT, Ghadirian P, Tung N, Olopade OI, Weber BL, McLennan J, Olivotto IA, Begin LR, Narod SA (2004) Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res 10(6):2029–2034PubMedCrossRefGoogle Scholar
  17. 17.
    Vaziri SA, Krumroy LM, Elson P, Budd GT, Darlington G, Myles J, Tubbs RR, Casey G (2001) Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis. Clin Cancer Res 7(7):1937–1945PubMedGoogle Scholar
  18. 18.
    Verhoog LC, Brekelmans CT, Seynaeve C, van den Bosch LM, Dahmen G, van Geel AN, Tilanus-Linthorst MM, Bartels CC, Wagner A, van den Ouweland A, Devilee P, Meijers-Heijboer EJ, Klijn JG (1998) Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 351:316–321PubMedCrossRefGoogle Scholar
  19. 19.
    Armes JE, Trute L, White D, Southey MC, Hammet F, Tesoriero A, Hutchins AM, Dite GS, McCredie MR, Giles GG, Hopper JL, Venter DJ (1999) Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. Cancer Res 59(8):2011–2017PubMedGoogle Scholar
  20. 20.
    Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, van de Vijver MJ, Farid LM, Venter D, Antoniou A, Storfer-Isser A, Smyth E, Steel CM, Haites N, Scott RJ, Goldgar D, Neuhausen S, Daly PA, Ormiston W, McManus R, Scherneck S, Ponder BAJ, Ford D, Peto J, Stoppa-Lyonnet D, Bignon Y-J, Struewing JP, Spurr NK, Bishop DT, Klijn JGM, Devilee P, Cornelisse CJ, Lasset C, Lenoir G, Barkardottir RB, Egilsson V, Hamann U, Chang-Claude J, Sobol H, Weber B, Stratton MR, Easton DF (1998) Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 90(15):1138–1145PubMedCrossRefGoogle Scholar
  21. 21.
    Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, Easton DF (2002) The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20(9):2310–2318PubMedCrossRefGoogle Scholar
  22. 22.
    Crook T, Crossland S, Crompton MR, Osin P, Gusterson BA (1997) p53 mutations in BRCA1-associated familial breast cancer. Lancet 350(9078):638–639PubMedCrossRefGoogle Scholar
  23. 23.
    Bane AL, Beck JC, Bleiweiss I, Buys SS, Catalano E, Daly MB, Giles G, Godwin AK, Hibshoosh H, Hopper JL, John EM, Layfield L, Longacre T, Miron A, Senie R, Southey MC, West DW, Whittemore AS, Wu H, Andrulis IL, O’Malley FP (2007) BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. Am J Surg Pathol 31(1):121–128PubMedCrossRefGoogle Scholar
  24. 24.
    Honrado E, Benitez J, Palacios J (2006) Histopathology of BRCA1- and BRCA2-associated breast cancer. Crit Rev Oncol/Hematol 59(1):27–39. doi: 10.1016/j.critrevonc.2006.01.006 CrossRefGoogle Scholar
  25. 25.
    Weitzel JN, Lagos V, Blazer KR, Nelson R, Ricker C, Herzog J, McGuire CG, Neuhausen S (2005) Prevalence of BRCA mutations and founder effect in high-risk Hispanic families. Cancer Epidemiol Biomark Prev 14(7):1666–1671CrossRefGoogle Scholar
  26. 26.
    Palacios J, Honrado E, Osorio A, Cazorla A, Sarrio D, Barroso A, Rodriguez S, Cigudosa JC, Diez O, Alonso C, Lerma E, Dopazo J, Rivas C, Benitez J (2005) Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers. Breast Cancer Res Treat 90(1):5–14PubMedCrossRefGoogle Scholar
  27. 27.
    Battifora H, Mehta P (1990) The checkerboard tissue block. An improved multitissue control block. Lab Investig 63(5):722–724PubMedGoogle Scholar
  28. 28.
    Press MF, Slamon DJ, Flom KJ, Park J, Zhou JY, Bernstein L (2002) Evaluation of her-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 20(14):3095–3105PubMedGoogle Scholar
  29. 29.
    Press MF, Spaulding B, Groshen S, Kaminsky D, Hagerty M, Sherman L, Christensen K, Edwards DP (2002) Monoclonal antibodies designed for immunohistochemical detection of progesterone receptor in archival breast cancer specimens. Steroids 67:799–813PubMedCrossRefGoogle Scholar
  30. 30.
    Mass RD, Press MF, Anderson S, Cobleigh MA, Vogel CL, Dybdal N, Leiberman G, Slamon DJ (2005) Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer 6(3):240–246PubMedCrossRefGoogle Scholar
  31. 31.
    Press MF, Sauter G, Bernstein L, Villalobos IE, Mirlacher M, Zhou JY, Wardeh R, Li YT, Guzman R, Ma Y, Sullivan-Halley J, Santiago A, Park JM, Riva A, Slamon DJ (2005) Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 11(18):6598–6607. doi: 10.1158/1078-0432.CCR-05-0636 PubMedCrossRefGoogle Scholar
  32. 32.
    Lukas J, Niu N, Press MF (2000) p53 mutations and expression in breast carcinoma in situ. Am J Pathol 156(1):183–191PubMedCrossRefGoogle Scholar
  33. 33.
    Wen WH, Reles A, Runnebaum IB, Sullivan-Halley J, Bernstein L, Jones LA, Felix JC, Kreienberg R, El-Naggar A, Press MF (1999) p53 mutations and expression in ovarian cancers: correlation with overall survival. Int J Gynecol Pathol 18(1):29–41PubMedCrossRefGoogle Scholar
  34. 34.
    Wen WH, Bernstein L, Lescallett J, Beazer-Barclay Y, Sullivan-Halley J, White M, Press MF (2000) Comparison of TP53 mutations identified by oligonucleotide microarray and conventional DNA sequence analysis. Cancer Res 60(10):2716–2722PubMedGoogle Scholar
  35. 35.
    Stendahl M, Ryden L, Nordenskjold B, Jonsson PE, Landberg G, Jirstrom K (2006) High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. Clin Cancer Res 12(15):4614–4618. doi: 10.1158/1078-0432.CCR-06-0248 PubMedCrossRefGoogle Scholar
  36. 36.
    Ravdin PM, Green S, Dorr TM, McGuire WL, Fabian C, Pugh RP, Carter RD, Rivkin SE, Borst JR, Belt RJ et al (1992) Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol 10(8):1284–1291PubMedGoogle Scholar
  37. 37.
    Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM (2003) Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 21(10):1973–1979PubMedCrossRefGoogle Scholar
  38. 38.
    Cui X, Schiff R, Arpino G, Osborne CK, Lee AV (2005) Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 23(30):7721–7735. doi: 10.1200/JCO.2005.09.004 PubMedCrossRefGoogle Scholar
  39. 39.
    Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, Milne RL, Gaudet M, Schmidt MK, Broeks A, Cox A, Fasching PA, Hein R, Spurdle AB, Blows F, Driver K, Flesch-Janys D, Heinz J, Sinn P, Vrieling A, Heikkinen T, Aittomaki K, Heikkila P, Blomqvist C, Lissowska J, Peplonska B, Chanock S, Figueroa J, Brinton L, Hall P, Czene K, Humphreys K, Darabi H, Liu J, Van’t Veer LJ, van Leeuwen FE, Andrulis IL, Glendon G, Knight JA, Mulligan AM, O’Malley FP, Weerasooriya N, John EM, Beckmann MW, Hartmann A, Weihbrecht SB, Wachter DL, Jud SM, Loehberg CR, Baglietto L, English DR, Giles GG, McLean CA, Severi G, Lambrechts D, Vandorpe T, Weltens C, Paridaens R, Smeets A, Neven P, Wildiers H, Wang X, Olson JE, Cafourek V, Fredericksen Z, Kosel M, Vachon C, Cramp HE, Connley D, Cross SS, Balasubramanian SP, Reed MW, Dork T, Bremer M, Meyer A, Karstens JH, Ay A, Park-Simon TW, Hillemanns P, Arias Perez JI, Rodriguez PM, Zamora P, Benitez J, Ko YD, Fischer HP, Hamann U, Pesch B, Bruning T, Justenhoven C, Brauch H, Eccles DM, Tapper WJ, Gerty SM, Sawyer EJ, Tomlinson IP, Jones A, Kerin M, Miller N, McInerney N, Anton-Culver H, Ziogas A, Shen CY, Hsiung CN, Wu PE, Yang SL, Yu JC, Chen ST, Hsu GC, Haiman CA, Henderson BE, Le Marchand L, Kolonel LN, Lindblom A, Margolin S, Jakubowska A, Lubinski J, Huzarski T, Byrski T, Gorski B, Gronwald J, Hooning MJ, Hollestelle A, van den Ouweland AM, Jager A, Kriege M, Tilanus-Linthorst MM, Collee M, Wang-Gohrke S, Pylkas K, Jukkola-Vuorinen A, Mononen K, Grip M, Hirvikoski P, Winqvist R, Mannermaa A, Kosma VM, Kauppinen J, Kataja V, Auvinen P, Soini Y, Sironen R, Bojesen SE, Dynnes Orsted D, Kaur-Knudsen D, Flyger H, Nordestgaard BG, Holland H, Chenevix-Trench G, Manoukian S, Barile M, Radice P, Hankinson SE, Hunter DJ, Tamimi R, Sangrajrang S, Brennan P, McKay J, Odefrey F, Gaborieau V, Devilee P, Huijts PE, Tollenaar R, Seynaeve C, Dite GS, Apicella C, Hopper JL, Hammet F, Tsimiklis H, Smith LD, Southey MC, Humphreys MK, Easton D, Pharoah P, Sherman ME, Garcia-Closas M (2011) Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the breast cancer association consortium studies. J Natl Cancer Inst 103(3):250–263. doi: 10.1093/jnci/djq526 PubMedCrossRefGoogle Scholar
  40. 40.
    Elledge RM, Lock-Lim S, Allred DC, Hilsenbeck SG, Cordner L (1995) p53 mutation and tamoxifen resistance in breast cancer. Clin Cancer Res 1(10):1203–1208PubMedGoogle Scholar
  41. 41.
    Peredo R, Sastre G, Serrano J, Hunter Mellado R (2001) Her-2/neu oncogene expression in Puerto Rican females with breast cancer. Cell Mol Biol 47(6):1025–1032PubMedGoogle Scholar
  42. 42.
    Weiss SE, Tartter PI, Ahmed S, Brower ST, Brusco C, Bossolt K, Amberson JB, Bratton J (1995) Ethnic differences in risk and prognostic factors for breast cancer. Cancer 76(2):268–274PubMedCrossRefGoogle Scholar
  43. 43.
    Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109(9):1721–1728. doi: 10.1002/cncr.22618 PubMedCrossRefGoogle Scholar
  44. 44.
    Lara-Medina F, Perez-Sanchez V, Saavedra-Perez D, Blake-Cerda M, Arce C, Motola-Kuba D, Villarreal-Garza C, Gonzalez-Angulo AM, Bargallo E, Aguilar JL, Mohar A, Arrieta O (2011) Triple-negative breast cancer in hispanic patients: High prevalence, poor prognosis, and association with menopausal status, body mass index, and parity. Cancer. doi: 10.1002/cncr.25961
  45. 45.
    Joslyn SA, West MM (2000) Racial differences in breast carcinoma survival. Cancer 88(1):114–123PubMedCrossRefGoogle Scholar
  46. 46.
    Weitzel JN, Robson M, Pasini B, Manoukian S, Stoppa-Lyoneet D, Lynch HT, McLennan J, Foulkes WD, Wagner T, Tung N, Ghadirian P, Olopade O, Isaacs C, Kim-Sing C, Møller P, Neuhausen SL, Metcalfe K, Sun P, Narod SA (2005) A comparison of bilateral breast cancers in BRCA carriers. Cancer Epidemiol Biomark Prev 14(6):1534–1538CrossRefGoogle Scholar
  47. 47.
    Arber DA (2002) Effect of prolonged formalin fixation on the immunohistochemical reactivity of breast markers. Appl Immunohistochem Mol Morphol 10(2):183–186PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2011

Authors and Affiliations

  • Veronica I. Lagos-Jaramillo
    • 1
  • Michael F. Press
    • 2
  • Charité N. Ricker
    • 3
  • Louis Dubeau
    • 2
  • Phuong L. Mai
    • 1
    • 4
  • Jeffrey N. Weitzel
    • 1
  1. 1.Division of Clinical Cancer GeneticsCity of HopeDuarteUSA
  2. 2.Department of PathologyUniversity of Southern CaliforniaLos AngelesUSA
  3. 3.Cancer Genetics ProgramUniversity of Southern CaliforniaLos AngelesUSA
  4. 4.Clinical Genetics Branch/DCEG/NCIRockvilleUSA

Personalised recommendations